JP2013512278A - Ｋ−ｒａｓ変異を含んだ癌を処置するための方法 - Google Patents

Ｋ−ｒａｓ変異を含んだ癌を処置するための方法 Download PDF

Info

Publication number
JP2013512278A
JP2013512278A JP2012542150A JP2012542150A JP2013512278A JP 2013512278 A JP2013512278 A JP 2013512278A JP 2012542150 A JP2012542150 A JP 2012542150A JP 2012542150 A JP2012542150 A JP 2012542150A JP 2013512278 A JP2013512278 A JP 2013512278A
Authority
JP
Japan
Prior art keywords
antibody
mutation
cancer
dll4
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012542150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512278A5 (enExample
Inventor
ティモシー シー． ヘイ
ワン−チン イェン
マーカス エム． フィッシャー
Original Assignee
オンコメッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコメッド ファーマシューティカルズ インコーポレイテッド filed Critical オンコメッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2013512278A publication Critical patent/JP2013512278A/ja
Publication of JP2013512278A5 publication Critical patent/JP2013512278A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012542150A 2009-12-01 2010-12-01 Ｋ−ｒａｓ変異を含んだ癌を処置するための方法 Pending JP2013512278A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26555909P 2009-12-01 2009-12-01
US61/265,559 2009-12-01
PCT/US2010/058511 WO2011068840A1 (en) 2009-12-01 2010-12-01 Methods for treating cancers comprising k-ras mutations

Publications (2)

Publication Number Publication Date
JP2013512278A true JP2013512278A (ja) 2013-04-11
JP2013512278A5 JP2013512278A5 (enExample) 2014-01-23

Family

ID=44115253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542150A Pending JP2013512278A (ja) 2009-12-01 2010-12-01 Ｋ−ｒａｓ変異を含んだ癌を処置するための方法

Country Status (5)

Country Link
US (2) US20110165162A1 (enExample)
EP (1) EP2506875A4 (enExample)
JP (1) JP2013512278A (enExample)
CA (1) CA2782299A1 (enExample)
WO (1) WO2011068840A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015030720A (ja) * 2013-08-07 2015-02-16 一丸ファルコス株式会社 キネシン抑制剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
PT2758073T (pt) 2011-09-23 2019-02-01 Oncomed Pharm Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CA3047125A1 (en) 2016-12-15 2018-06-21 The Regents Of The University Of California Compositions and methods for treating cancer
US12246067B2 (en) 2018-06-19 2025-03-11 Biontech Us Inc. Neoantigens and uses thereof
AU2019380595A1 (en) 2018-11-15 2021-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with VEGF/DLL4 binding agent
CN112394168B (zh) * 2019-08-15 2023-02-14 中山大学附属第六医院 IgA2检测试剂在制备KRAS突变型结直肠癌诊断剂方面的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042236A2 (en) * 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
ES2334953T3 (es) * 1995-06-28 2010-03-17 Imperial Cancer Research Technology Limited Secuencias de nucleotidos y proteinas de genes delta de vertebrados y metodos basados en los mismos.
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US20060122373A1 (en) * 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
DE69837601T2 (de) * 1997-05-14 2007-12-27 Asahi Kasei Kabushiki Kaisha Neuer hemmer der differentierung
US6004528A (en) * 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
EP1409005A1 (en) * 2001-07-25 2004-04-21 Lorantis Limited Modulators of notch signalling for use in immunotherapy
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
WO2003042246A2 (en) * 2001-11-14 2003-05-22 Lorantis Limited Inhibitors of the notch signalling pathway for use in the treatment of cancer
CA2469204A1 (en) * 2001-12-07 2003-06-19 Regents Of The University Of Michigan Prospective identification and characterization of breast cancer stem cells
GB0218879D0 (en) * 2002-08-14 2002-09-25 Lorantis Ltd Medical treatment
AU2003267563A1 (en) * 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
WO2007028110A2 (en) * 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
WO2007070671A2 (en) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
US20080014196A1 (en) * 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042236A2 (en) * 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015030720A (ja) * 2013-08-07 2015-02-16 一丸ファルコス株式会社 キネシン抑制剤

Also Published As

Publication number Publication date
EP2506875A1 (en) 2012-10-10
US20160243223A1 (en) 2016-08-25
EP2506875A4 (en) 2013-11-27
WO2011068840A1 (en) 2011-06-09
US20110165162A1 (en) 2011-07-07
CA2782299A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
US9206256B2 (en) DDR1-binding agents and methods of use thereof
JP6170496B2 (ja) Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
JP2013512278A (ja) Ｋ−ｒａｓ変異を含んだ癌を処置するための方法
EP3303379B1 (en) Tigit-binding agents and uses thereof
CA2729306C (en) Notch-binding agents and antagonists and methods of use thereof
JP6335896B2 (ja) Ｒｓｐｏ３結合剤およびその使用法
US20180346571A1 (en) Pd-l1-binding agents and uses thereof
EP2911691B1 (en) Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9416178B2 (en) Jagged-binding agents and uses thereof
JP2015517529A (ja) Ｎｏｔｃｈ２／３抗体によって癌を治療するための方法
US9480744B2 (en) Methods for treating melanoma
WO2018017864A2 (en) Pvrig-binding agents and uses thereof
US20170266276A1 (en) Combination Therapy For Treatment of Cancer
US20170044268A1 (en) Immunotherapy with Binding Agents
US20160324961A1 (en) Methods for Treating Cancer with DLL4 Antagonists
JP2015502958A (ja) がんの処置のための併用療法
JP2016512533A (ja) Ｍｅｔ結合剤およびその使用
JP2018531994A (ja) がんの処置のための方法および組成物
US20170157245A1 (en) Treatment of gastric cancer
JP2017526356A (ja) Ｒｓｐｏ１結合剤およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160421

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160527